Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | $21.4B | $24.0B | $26.5B | $29.6B | $31.6B | $32.8B | $33.3B | $33.6B | $28.0B | $25.7B | $26.1B | $24.7B | $23.0B | $22.5B | $22.1B | $24.4B | $26.6B | $37.4B | $44.4B | $45.8B |
Discover the top 20 best undervalued stocks to buy for Nov 2024, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Nov 2024, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Nov 2024.
As of today, AstraZeneca PLC's last 12-month Revenue is $51.2B, based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, AstraZeneca PLC's Revenue growth was 13.8%. The average annual Revenue growth rates for AstraZeneca PLC have been 22.9% over the past three years, 16.2% over the past five years.
Over the last year, AstraZeneca PLC's Revenue growth was 13.8%, which is higher than industry growth of 0.1%. It indicates that AstraZeneca PLC's Revenue growth is Good.